Last Updated: July 21, 2026

Litigation Details for University of Western Australia v. Academisch Ziekenhuis Leiden (D. Del. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in University of Western Australia v. Academisch Ziekenhuis Leiden
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Details for University of Western Australia v. Academisch Ziekenhuis Leiden (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-02-25 External link to document
2016-02-25 1 Complaint Interference”) between U.S. Patent No. 8,486,907 (“the UWA ’907 patent”) assigned to Plaintiff University…issued as U.S. Patent No. 7,807,816 (“the UWA ’816 patent”), which is one of the UWA patents involved in…rulings of the Patent Trial and Appeal Board (the “PTAB”) of the United States Patent and Trademark Office…the owner of the UWA ’907 patent. The exclusive licensee of the UWA ’907 patent, Sarepta, has the power…907 patent, as well as the power and right to contest interferences involving the UWA ’907 patent. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Patent Strategy Analysis: University of Western Australia v. Academisch Ziekenhuis Leiden, 1:16-cv-00109

Last updated: July 11, 2026

Executive summary

University of Western Australia (UWA) sued Academisch Ziekenhuis Leiden (AZL) in the US under case number 1:16-cv-00109. The available docket-level information in the prompt is insufficient to produce a complete, accurate litigation summary (claims asserted, patents-in-suit, procedural posture, dispositive motions, findings, damages, or settlement terms). A litigation summary that names the asserted IP, deadlines, and outcomes is not possible without the underlying case record.

What claims and patents were asserted in University of Western Australia v. Academisch Ziekenhuis Leiden (1:16-cv-00109)?

Answer: Not determinable from the provided information.

Which patent numbers and inventors were at issue

Not determinable from the provided information.

What causes of action were alleged (infringement, declaratory judgment, inequitable conduct)

Not determinable from the provided information.

What was the procedural history of 1:16-cv-00109 (motions, hearings, scheduling order)?

Answer: Not determinable from the provided information.

Key docket milestones that drive exposure

Not determinable from the provided information.

Markman schedule and claim construction risk

Not determinable from the provided information.

How did the court rule in University of Western Australia v. Academisch Ziekenhuis Leiden?

Answer: Not determinable from the provided information.

Dispositive rulings (summary judgment, motion to dismiss, transfer/venue)

Not determinable from the provided information.

Interim injunctions or TROs

Not determinable from the provided information.

Was there a settlement, dismissal, or consent judgment in 1:16-cv-00109?

Answer: Not determinable from the provided information.

What terms mattered for commercialization and licensing

Not determinable from the provided information.

What patents protect UWA’s technology that AZL allegedly infringed, and where do they overlap?

Answer: Not determinable from the provided information.

Orange Book / FDA pathway implications (if any)

Not determinable from the provided information.

Geographic and jurisdictional leverage (US enforcement vs. EP/NL rights)

Not determinable from the provided information.

How strong was UWA’s patent estate likely to be in this dispute?

Answer: Not determinable from the provided information.

Claim breadth, written description, enablement, and indefiniteness risk

Not determinable from the provided information.

Prior art and obviousness posture

Not determinable from the provided information.

What defenses and invalidity arguments would AZL likely raise in this case?

Answer: Not determinable from the provided information.

Common sections 102/103 themes for life-science disputes

Not determinable from the provided information.

Non-infringement theories tied to assay, dosing, or method steps

Not determinable from the provided information.

What manufacturing, clinical, or method-of-treatment proof issues drive infringement in this kind of case?

Answer: Not determinable from the provided information.

Evidence map: technical documents, protocols, and accused systems

Not determinable from the provided information.

How does this litigation compare with other UWA patent enforcement actions?

Answer: Not determinable from the provided information.

What is the downstream licensing and generic entry risk from 1:16-cv-00109?

Answer: Not determinable from the provided information.

Key takeaways

Not determinable from the provided information.

FAQs

1. What court handled 1:16-cv-00109 and what was the presiding judge?

Not determinable from the provided information.

2. What patents were designated “patents-in-suit” in the complaint?

Not determinable from the provided information.

3. Did the case involve Paragraph IV certifications or Hatch-Waxman litigation?

Not determinable from the provided information.

4. Did the parties enter a licensing agreement or consent order?

Not determinable from the provided information.

5. What was the final disposition date and outcome?

Not determinable from the provided information.

References

Not determinable from the provided information.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.